Affordable Access

deepdyve-link
Publisher Website

Influence of vitamin D supplementation on lipid levels in polycystic ovary syndrome patients: a meta-analysis of randomized controlled trials.

Authors
  • Jin, Bihui1
  • Qian, Lingbo2
  • Fu, Xiaohua1
  • Zhu, Jing1
  • Shu, Jing1
  • 1 Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. , (China)
  • 2 School of Basic Medical Sciences & Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China. , (China)
Type
Published Article
Journal
The Journal of international medical research
Publication Date
Aug 01, 2020
Volume
48
Issue
8
Identifiers
DOI: 10.1177/0300060520935313
PMID: 32776821
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Observational studies have shown that circulating vitamin D (VitD) deficiency is associated with atherogenic lipid patterns among polycystic ovary syndrome (PCOS) patients. However, interventional studies have shown inconsistent results. The aim of this meta-analysis was to investigate how VitD supplementation influences lipid indices in PCOS patients. The authors searched four electronic databases through August 2019 to identify randomized controlled trials (RCTs) that assessed the effect of VitD intervention on serum lipids among PCOS patients. Mean differences were generated for statistical evaluation. We included eight studies and performed nine comparisons across 467 participants. VitD supplementation reduced serum triglyceride levels (-11.88 mg/dL; 95% confidence interval [CI]: -17.03 to -6.73), total cholesterol (-9.09 mg/dL; 95% CI: -14.90 to -3.29), low-density lipoprotein cholesterol (-5.22 mg/dL; 95% CI: -10.32 to -0.13), and very-low-density lipoprotein cholesterol (-2.43 mg/dL; 95% CI: -3.69 to -1.17) compared with no VitD supplementation. However, high-density lipoprotein cholesterol levels showed no differences with or without VitD supplementation (-0.39 mg/dL; 95% CI: -1.39 to 0.61). VitD supplementation improved serum lipid levels among PCOS patients, but serum high-density lipoprotein cholesterol levels were not changed. VitD intervention might benefit PCOS patients who are at high risk of an atherogenic lipid profile.

Report this publication

Statistics

Seen <100 times